HallaNimeiriMD

Oncology • Chicago, IL

Associate Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg Medical School

Join to view full profile

Dr. Nimeiri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nimeiri's full profile

Already have an account?

Office
251 E Huron St
Chicago, IL 60611
Phone+1 312-926-2000

Fax+1 312-926-2411

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2005 - 2008
Mercy Catholic Medical CenterResidency, Internal Medicine, 2002 - 2005
University of Khartoum Faculty of MedicineClass of 1992

Certifications & Licensure

IL State Medical License 2005 - 2026
PA State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps Start of enrollment: 2009 Feb 01
Terminated
Not Applicable
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery Start of enrollment: 2009 Aug 01
Completed
Phase 2
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2009 Nov 17
Completed
Phase 1
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer Start of enrollment: 2011 Nov 01
Terminated
Phase 1, Phase 2
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Start of enrollment: 2011 Dec 12
Completed
Phase 1, Phase 2
Study of Vitamin D in Untreated Metastatic Colorectal Cancer Start of enrollment: 2012 Apr 13
Completed
Phase 2
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2012 Oct 05
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study...
Yoshiaki Nakamura, Kristiyana Kaneva, Christine Lo, Daniel Neems, Jonathan E Freaney
Clinical Cancer Research. 2024-11-08
Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non-Small Cell Lung Cancer.
Dwight Owen, Rotem Ben-Shachar, Josephine Feliciano, Lisa Gai, Kyle A Beauchamp
JAMA Network Open. 2024-11-04
Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy.
Ryan D Gentzler, John Guittar, Akash Mitra, Wade T Iams, Terri Driessen
Oncology and Therapy. 2024-09-01

Press Mentions

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer CareNovember 11th, 2024
Tempus Expands Immuno-Oncology Portfolio with Launch of AI-Enabled, Multimodal Immune Profile Algorithmic TestsJuly 16th, 2024